Highlight
- Helicobacter pylori (H. pylori) infection is associated with an increased risk of colorectal cancer (CRC), especially in genetically susceptible individuals.
- The risk is further elevated in individuals seropositive for key H. pylori virulence factors: CagA, HpaA, Omp, and HP0305.
- H. pylori eradication treatment reduces CRC risk in the Shandong Intervention Trial (SIT) but shows benefit mainly among high genetic risk subgroups in the larger Mass Intervention Trial in Linqu (MITS).
- Long-term follow-up up to nearly 30 years supports a sustained protective effect of successful H. pylori eradication in select populations.
Background
Specialty calculators
For clinical reference; use professional judgment.
